Vince and Associates Clinical Research Inc
Overland Park, Kansas, 66212, United States
NCT Number: NCT03799900
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Overland Park, Kansas, 66212, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Part 1
Part 2, Qualification Phase:
Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner
Part 2, Treatment Phase:
Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Part 1
Part 2, Qualification Phase:
Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner
Part 2, Treatment Phase:
Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose
The drug liking VAS measures the participant's liking for the drug and is scored from 0 to 100, with 0 reflecting "Strong disliking" and 100 reflecting "Strong liking".
Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose
Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose
Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose
Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose
Time frame: Treatment Phase: Hour 0 and up to 24 Hours post-dose
Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose
Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose
Time frame: Part 1: 6 weeks, Part 2: 9 weeks
Time frame: Part 1: 6 weeks, Part 2: 9 weeks
Time frame: Part 1: 6 weeks, Part 2: 9 weeks
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (least severe) to 5 (most severe).
Naurex, Inc, an affiliate of Allergan plc
Industry
A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05256108
Human Abuse Potential, Neurologic Manifestations
Columbus, Ohio, United States
View Trial Details